Esperion Therapeutics, Inc. (ESPR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
3891 Ranchero Drive
Ann Arbor, MI 48108
United States of America (the)
Phone
734 887 3903
Website
Sector
Healthcare
Industry
Biotechnology
Employees
304
First IPO Date
June 26, 2013
| Name | Title | Pay | Year Born |
| Sheldon L. Koenig | President, Chief Executive Officer & Director | 1.43M | 1966 |
| John Harlow | Chief Commercial Officer | 582,940 | 1976 |
| Benjamin O. Looker | Chief Legal and Corporate Affairs Officer | 696,350 | 1982 |
| Benjamin Halladay | Chief Financial Officer | 755,083 | 1986 |
| Tiffany Aldrich | Associate Director of Corporate Communications | 0 | N/A |
| Glenn Brame | Chief Technical Operations Officer | 0 | 1957 |
| Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development | 0 | N/A |
| Betty Jean Swartz | Chief Business Officer | 0 | N/A |
| LeAnne Bloedon | Vice President & Head of Development | 0 | N/A |
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.